CC-98633

Overview

CC-98633 is a BCMA targeted Chimeric Antigen Receptor (CAR) T Cell therapy that is being evaluated in multiple myeloma.

SparkCures ID 381
Developed By Juno Therapeutics, a Subsidiary of Celgene
Generic Name CC-98633
Treatment Classifications
Treatment Targets

Clinical Trials

Resources

There are no resources, links or videos to display for this treatment.